Clinical Trials ·
The study of LY3437943, also known as Retatrutide, aims to evaluate its impact on weight loss in individuals with obesity or overweight. This clinical trial is designed to gather comprehensive data over an 18-month period, involving up to 18 visits from participants. Such research is crucial for understanding the efficacy of Retatrutide in managing body weight, a key factor in obesity-related health issues.
What this source covers
The source details a clinical trial registered under NCT04881760, which investigates the effects of LY3437943 in participants diagnosed with obesity or classified as overweight. The primary objective of the study is to assess how this investigational drug influences body weight loss over the course of approximately 18 months. Participants will attend up to 18 visits, allowing for thorough monitoring and data collection.
Why it matters for Retatrutide research
This trial is significant in the context of Retatrutide research as it seeks to establish a clearer understanding of the drug's effectiveness in promoting weight loss. Given the increasing prevalence of obesity, effective pharmacological interventions are essential. The outcomes of this study could provide insights that may inform future treatment protocols and guidelines for managing obesity.
Key findings or claims
- The study focuses on participants with obesity or overweight.
- LY3437943 is the investigational drug being tested.
- The trial duration is approximately 18 months.
- Participants may have up to 18 visits during the study.
- The primary aim is to assess the impact on body weight loss.
Context and prior work
Retatrutide is part of a growing body of research surrounding GLP-1, GIP, and glucagon receptor agonists, which have shown promise in weight management. Previous studies have indicated that such agents can lead to significant weight loss and improvements in metabolic parameters. This trial adds to the existing literature by focusing specifically on Retatrutide's role in weight loss, potentially contributing to a broader understanding of its therapeutic applications.
Practical takeaways for researchers
Researchers interested in obesity treatment should monitor the outcomes of this trial closely, as it may provide valuable data on the efficacy of Retatrutide. Understanding the mechanisms by which this drug promotes weight loss could inform future research directions and therapeutic strategies. Additionally, insights gained from this trial could enhance knowledge regarding patient responses to GLP-1 and GIP receptor agonists.
FAQ
What is LY3437943?
LY3437943, also known as Retatrutide, is an investigational drug being studied for its effects on weight loss in individuals with obesity or overweight.
How long will the study last?
The study is expected to last approximately 18 months, during which participants will attend up to 18 visits.
What is the primary goal of the study?
The primary goal is to evaluate how LY3437943 affects body weight loss in participants with obesity or overweight.
Source: ClinicalTrials.gov · NCT04881760 · published 2023-09-13.